Melian Agustin
Known title: Chief Medical OfficerCIK: 0001818064
Associated companies
Transaction History
| KLRS | ▼ Sell | Open Market | 10,678 | $249K | 10/4/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 4,711 | $114K | 10/4/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 2,967 | $75K | 10/4/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 333 | $9K | 10/4/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 3,750 | $90K | 9/28/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 2,950 | $71K | 9/17/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 800 | $19K | 9/15/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 18,586 | $372K | 7/2/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 18,212 | $435K | 4/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI
Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.